ADMA Biologics, Inc. (ADMA)
9.51
+0.18
(+1.93%)
USD |
NASDAQ |
Sep 02, 16:00
9.515
0.00 (0.00%)
Pre-Market: 20:00
ADMA Biologics Research and Development Expense (TTM) : 11.52M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 11.52M |
| March 31, 2026 | 6.532M |
| December 31, 2025 | 4.761M |
| September 30, 2025 | 3.776M |
| June 30, 2025 | 2.66M |
| March 31, 2025 | 2.189M |
| December 31, 2024 | 1.813M |
| September 30, 2024 | 1.868M |
| June 30, 2024 | 2.051M |
| March 31, 2024 | 2.895M |
| December 31, 2023 | 3.30M |
| September 30, 2023 | 3.929M |
| June 30, 2023 | 4.375M |
| March 31, 2023 | 3.845M |
| December 31, 2022 | 3.614M |
| September 30, 2022 | 3.268M |
| June 30, 2022 | 2.997M |
| March 31, 2022 | 3.282M |
| December 31, 2021 | 3.646M |
| September 30, 2021 | 3.930M |
| June 30, 2021 | 4.868M |
| March 31, 2021 | 5.366M |
| December 31, 2020 | 5.907M |
| September 30, 2020 | 5.358M |
| June 30, 2020 | 4.141M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.002M |
| December 31, 2019 | 2.344M |
| September 30, 2019 | 1.734M |
| June 30, 2019 | 2.560M |
| March 31, 2019 | 3.515M |
| December 31, 2018 | 3.926M |
| September 30, 2018 | 5.935M |
| June 30, 2018 | 6.432M |
| March 31, 2018 | 6.319M |
| December 31, 2017 | 6.230M |
| September 30, 2017 | 4.949M |
| June 30, 2017 | 4.812M |
| March 31, 2017 | 6.853M |
| December 31, 2016 | 7.688M |
| September 30, 2016 | 9.102M |
| June 30, 2016 | 9.536M |
| March 31, 2016 | 7.642M |
| December 31, 2015 | 7.016M |
| September 30, 2015 | 6.939M |
| June 30, 2015 | 6.310M |
| March 31, 2015 | 6.588M |
| December 31, 2014 | 9.517M |
| September 30, 2014 | 10.55M |
| June 30, 2014 | 10.48M |
| March 31, 2014 | 12.17M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Erasca, Inc. | 108.88M |
| Krystal Biotech, Inc. | 53.39M |
| Vericel Corp. | 29.17M |
| Emergent BioSolutions, Inc. | 45.30M |
| Exelixis, Inc. | 824.32M |